ImmunoGen quadruples revenue on ADC demand; CytoDyn raises $14.5M for HIV drug;

@FierceBiotech: J&J wins FDA panel blessing for hepatitis C blockbuster hopeful. Story | Follow @FierceBiotech

@JohnCFierce: Let's see. Friday. Today Gilead's team will take its bows at the sofosbuvir panel. Then a vote and break for celebratory drinks, pictures. | Follow @JohnCFierce

@DamianFierce: Aerie prices $67M IPO and becomes 40th biotech to go public this year. More | Follow @DamianFierce

@EmilyMFierce: When is a medical treatment unnecessary? Article | Follow @EmilyMFierce

> Washington's CytoDyn ($CYDY) raised $14.5 million in private equity to fund development of its HIV therapy, which has received the FDA's "fast track" designation. Release

> Thanks to a bevy of licensing deals and royalties from Roche's ($RHHBY) Kadcyla, antibody-drug conjugate luminary ImmunoGen ($IMGN) more than quadrupled its revenue to $17.2 million last quarter and cut its net loss by almost 60% to $11.2 million. Results

> The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended Actelion's ($ATLN) Opsumit and Lundbeck's Brintellix for approval. Both drugs have already secured the FDA's blessing. Story

> The FDA is recommending restricting patient access to hydrocodone painkillers like Vicodin. Article

Medical Device News

@FierceMedDev: Myriad slaps Quest with BRCA cancer test patent suit. Article | Follow @FierceMedDev

@MarkHFierce: Stryker paid $13.2M to settle SEC bribery charges but doesn't admit or deny any wrongdoing. Story | Follow @MarkHFierce

@MichaelGFierce: This week's Chutes & Ladders from FierceBiotech: Eli Lilly's board elects multinational financial leader, and more. Item | Follow @MichaelGFierce

> Med tech VC Versant raising $250M new fund amid sluggish market. More

> Report: ICU Medical pulls the plug on billion-dollar buyout effort. News

> ResMed's respiratory device sales drive more global growth. Story

Pharma News

@FiercePharma: ICYMI: GSK saves $431M moving retirees to private healthcare exchanges. Story | Follow @FiercePharma

@EricPFierce: South Africa's Aspen Pharmacare is a major generic drugmaker poised to get bigger. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: With Aptalis sale a no-go, TPG plots IPO instead. More | Follow @CarlyHFierce

> Celgene raises earnings forecast third time. More

> FDA again finds itself playing role as pain med police. Story

> Japan's frustrated Eisai loses fight with DEA. Article

Suggested Articles

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Cour unveiled phase 2 data showing that its treatment cut levels of pro-inflammatory cytokines and protected the gut in patients with celiac disease.

Three years after Bayer and gene-editing biotech CRISPR Therapeutics joined forces to launch and run Casebia Therapeutics.